Athira Pharma - ATHA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $24.00
  • Forecasted Upside: 697.34 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.01
▼ -0.11 (-3.53%)

This chart shows the closing price for ATHA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athira Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHA

Analyst Price Target is $24.00
▲ +697.34% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Athira Pharma in the last 3 months. The average price target is $24.00, with a high forecast of $51.00 and a low forecast of $5.00. The average price target represents a 697.34% upside from the last price of $3.01.

This chart shows the closing price for ATHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Athira Pharma. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2022MizuhoInitiated CoverageBuy$6.00N/A
6/23/2022Stifel NicolausDowngradeBuy ➝ Hold$36.00 ➝ $5.00Low
6/23/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
6/22/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
5/10/2022BTIG ResearchInitiated CoverageBuy$33.00Low
4/21/2022Berenberg BankInitiated CoverageBuy$33.00Medium
3/25/2022JMP SecuritiesReiterated RatingBuy$51.00High
12/15/2021The Goldman Sachs GroupInitiated CoverageNeutral$16.00High
8/30/2021JMP SecuritiesReiterated RatingBuy$51.00Low
10/13/2020Jefferies Financial GroupInitiated CoverageBuy$30.00High
10/13/2020JMP SecuritiesInitiated CoverageOutperform$51.00High
10/13/2020Stifel NicolausInitiated CoverageBuy$36.00High
10/13/2020The Goldman Sachs GroupInitiated CoverageBuy$53.00High
(Data available from 9/26/2017 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2022
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/30/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/29/2022
  • 9 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/29/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
6/28/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/28/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/27/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/26/2022

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Athira Pharma logo
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $3.01
Low: $2.98
High: $3.20

50 Day Range

MA: $3.49
Low: $3.01
High: $3.96

52 Week Range

Now: $3.01
Low: $2.53
High: $16.65

Volume

257,781 shs

Average Volume

526,692 shs

Market Capitalization

$113.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Athira Pharma?

The following Wall Street research analysts have issued stock ratings on Athira Pharma in the last twelve months: Berenberg Bank, BTIG Research, Jefferies Financial Group Inc., JMP Securities, Mizuho, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ATHA.

What is the current price target for Athira Pharma?

6 Wall Street analysts have set twelve-month price targets for Athira Pharma in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 697.3%. JMP Securities has the highest price target set, predicting ATHA will reach $51.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $5.00 for Athira Pharma in the next year.
View the latest price targets for ATHA.

What is the current consensus analyst rating for Athira Pharma?

Athira Pharma currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATHA, but not buy more shares or sell existing shares.
View the latest ratings for ATHA.

What other companies compete with Athira Pharma?

How do I contact Athira Pharma's investor relations team?

The company's listed phone number is 425-620-8501 and its investor relations email address is [email protected] The official website for Athira Pharma is athira.com. Learn More about contacing Athira Pharma investor relations.